First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.

ABSTRACT:

Background

DepoVax is a novel non-emulsion depot-forming vaccine platform with the capacity to significantly enhance the immunogenicity of peptide cancer antigens. Naturally processed HLA-A2 restricted peptides presented by breast, ovarian and prostate cancer cells were used as antigens to create a therapeutic cancer vaccine, DPX-0907.

Methods

A phase I clinical study was designed to examine the safety and immune activating potential of DPX-0907 in advanced stage breast, ovarian and prostate cancer patients. A total of 23 late stage cancer patients were recruited and were divided into two dose/volume cohorts in a three immunization protocol.

Results

DPX-0907 was shown to be safe with injection site reactions being the most commonly reported adverse event. All breast c

SUBMITTER: Berinstein NL 

PROVIDER: S-EPMC3479010 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature